The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression

Laurie E. Littlepage, Adam S. Adler, Hosein Kouros-Mehr, Guiqing Huang, Jonathan Chou, Sheryl R. Krig, Obi L. Griffi th, James E. Korkola, Kun Qu, Devon A. Lawson, Qing Xue, Mark D. Sternlicht, Gerrit J P Dijkgraaf, Paul Yaswen, Hope S. Rugo, Colleen A Sweeney, Colin C. Collins, Joe W. Gray, Howard Y. Chang, Zena Werb

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression'. Together they form a unique fingerprint.

Medicine & Life Sciences